TRSB.F Stock Overview
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 3/6 |
3SBio Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.80 |
52 Week High | HK$0.80 |
52 Week Low | HK$0.80 |
Beta | 0.76 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -66.94% |
Recent News & Updates
Recent updates
Shareholder Returns
TRSB.F | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 0.9% | 0.4% |
1Y | n/a | 10.3% | 28.8% |
Return vs Industry: Insufficient data to determine how TRSB.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how TRSB.F performed against the US Market.
Price Volatility
TRSB.F volatility | |
---|---|
TRSB.F Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TRSB.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TRSB.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 5,160 | Jing Lou | https://www.3sbio.com |
3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People’s Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis.
3SBio Inc. Fundamentals Summary
TRSB.F fundamental statistics | |
---|---|
Market cap | US$1.71b |
Earnings (TTM) | US$239.03m |
Revenue (TTM) | US$891.54m |
7.2x
P/E Ratio1.9x
P/S RatioIs TRSB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TRSB.F income statement (TTM) | |
---|---|
Revenue | CN¥6.37b |
Cost of Revenue | CN¥1.11b |
Gross Profit | CN¥5.25b |
Other Expenses | CN¥3.55b |
Earnings | CN¥1.71b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0.70 |
Gross Margin | 82.52% |
Net Profit Margin | 26.81% |
Debt/Equity Ratio | 26.4% |
How did TRSB.F perform over the long term?
See historical performance and comparison